Enlivex Therapeutics Ltd. (ENLV): Price and Financial Metrics


Enlivex Therapeutics Ltd. (ENLV): $4.38

-0.05 (-1.13%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ENLV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ENLV Stock Price Chart Interactive Chart >

Price chart for ENLV

ENLV Price/Volume Stats

Current price $4.38 52-week high $8.64
Prev. close $4.43 52-week low $3.62
Day low $4.32 Volume 25,245
Day high $4.47 Avg. volume 30,482
50-day MA $4.28 Dividend yield N/A
200-day MA $4.61 Market Cap 80.64M

Enlivex Therapeutics Ltd. (ENLV) Company Bio


Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate, which is in Phase IIb clinical trial in patients with severe sepsis; that is in investigator-initiated Phase II clinical trial for the treatment of COVID-19 patients in severe and critical conditions; and which is in Phase IIa clinical trial for the prevention of Graft Versus Host Disease in allogeneic hematopoietic stem cell transplants (HSCT) patients. The company is also developing Allocetra for the prevention of complications associated with bone marrow transplantations and/or HSCT, and acute multiple organ failure. It also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor T-Cell therapy and therapies targeting T-Cell receptor therapy. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.


ENLV Latest News Stream


Event/Time News Detail
Loading, please wait...

ENLV Latest Social Stream


Loading social stream, please wait...

View Full ENLV Social Stream

Latest ENLV News From Around the Web

Below are the latest news stories about ENLIVEX THERAPEUTICS LTD that investors may wish to consider to help them evaluate ENLV as an investment opportunity.

Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors

Nes-Ziona, Israel, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that an independent Data and Safety Monitoring Board (DSMB) has completed its prespecified data review for the first cohort of patients in the Company’s ongoing Phase I/II cell therapy clinical trial of AllocetraTM in patients with advanced-stage solid tumors (clinicaltrials.gov Identifier: NCT05581719). The

Yahoo | January 25, 2023

Enlivex gets French and Belgian regulatory nod to expand mid-stage sepsis trial

Enlivex Therapeutics (ENLV) said it had got approval from French and Belgian regulatory agencies to expand its phase two sepsis trial into those countries. Read more here.

Seeking Alpha | January 4, 2023

Enlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and Belgium

Nes-Ziona, Israel, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the French Agency for Food, Environmental and Occupational Health and Safety (ANSES) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) have cleared the amended protocol of the Company’s Phase II trial evaluating Allocetra™ in patients with sepsis. The approved protocol, which prev

Yahoo | January 4, 2023

EQS-News: A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial

EQS-News: Enlivex Therapeutics, Ltd. A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial 07.12.2022 / 14:40 CET/CEST The issuer is solely responsible for the content of this announcement. Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced

Wallstreet:Online | December 7, 2022

EQS-News: Enlivex Therapeutics, Ltd.: A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial

EQS-News: Enlivex Therapeutics, Ltd. A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial 07.12.2022 / 14:40 CET/C…

Finanz Nachrichten | December 7, 2022

Read More 'ENLV' Stories Here

ENLV Price Returns

1-mo 11.24%
3-mo 2.82%
6-mo -13.61%
1-year -17.98%
3-year -45.11%
5-year -81.44%
YTD 11.24%
2022 -37.00%
2021 -25.86%
2020 0.46%
2019 36.22%
2018 -66.38%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7207 seconds.